Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) recovered -4.76% of its value since hitting low of $1.05. The recent move of -16.67% drop pushed the stock to close at $1 when trading ended on 02/12/2018. At recent session, the prices were hovering between $1 and $1.1. This company shares are 100% off its target price of $2 and the current market capitalization stands at $19.42M. The recent change has given its price a -26.02% deficit over SMA 50 and -75% deficit over its 52-week high. The stock witnessed -24.53% declines, -36.51% declines and -37.5% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TTNP’s volatility during a week at 11.44% and during a month it has been found around 9.11%.Titan Pharmaceuticals, Inc. (TTNP) Top Holders
Institutional investors currently hold around $2 million or 9% in TTNP stock. Look at its top three institutional owners. Vanguard Group Inc owns $567 thousand in Titan Pharmaceuticals, Inc., which represents roughly 2.92% of the company’s market cap and approximately 28.35% of the institutional ownership. Similar statistics are true for the second largest owner, Renaissance Technologies Llc, which owns 440,400 shares of the stock are valued at $528 thousand. The third largest holder is Municipal Employees’ Retirement System Of Michigan, which currently holds $364 thousand worth of this stock and that ownership represents nearly 1.87% of its market capitalization.
At the end of 09/30/2017 reporting period, 11 institutional holders increased their position in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) by some 194,242 shares, 22 decreased positions by 1,019,236 and 15 held positions by 672,366. That puts total institutional holdings at 1,885,844 shares, according to SEC filings. The stock grabbed 4 new institutional investments totaling 26,576 shares while 11 institutional investors sold out their entire positions totaling 657,687 shares.Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Insider Trades
Multiple company employees have indulged in significant insider trading. Titan Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Akers Joseph A has acquired 13,000 shares of Titan Pharmaceuticals, Inc. (TTNP) in trading session dated Jul. 19, 2016. These shares are worth $63,050 and were traded at $4.85 each. The SEC filing shows that Bhonsle Sunil performed a purchase of 10,000 shares. The President and CEO added these shares by way of transaction on Jul. 18, 2016. The company’s shares were assimilated at $4.96 per share worth to an investment of some $49,600 on account of Bhonsle Sunil.
Director, Mcnab James R, purchased 20,000 common shares of Titan Pharmaceuticals, Inc. (TTNP) in the open market. In a transaction dated May. 31, 2016, the shares were bought at an average price of $7.03, giving away a sum of $140,600. After this purchase, 100,000 common shares of TTNP are directly owned by the insider, with total stake valued at $100,000.
In the transaction dated Feb. 22, 2016, the great number of shares acquired came courtesy the President and CEO; Bhonsle Sunil added a total of 11,763 shares at an average price of $3.56, amounting to approximately $41,876. The insider now directly owns 180,262 shares worth $180,262.Titan Pharmaceuticals, Inc. (TTNP) Analyst Guide
Several analysts have released their opinion on Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), with 0 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 3 average brokerage recommendation.